AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22500909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (0.5 mL fentanyl combined with bupivacaine 15 mg)
Number of subjects: 90
Study 22500909 — intervention group
Group type: COMPARATOR
Intervention: Control (0.5 mL distilled water combined with bupivacaine 15 mg)
Number of subjects: 90
Study 20595645 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry beverage (Str; containing 10 g freeze-dried fruit)
Number of subjects: 24
Study 20595645 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (Pbo)
Number of subjects: 24
Study 18006422 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational quality improvement intervention
Number of subjects: 47
Study 18006422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 16708293 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative vapreotide
Number of subjects: 381
Study 16708293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 14659354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8, repeated every 3 weeks
Number of subjects: 99
Study 14659354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8
Number of subjects: 99
Study 10870037 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (GLU; 0.017 mg/kg i.m.)
Number of subjects: 6
Study 10870037 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (GLU; 0.017 mg/kg i.m.) + hCRH (2.0 µg/kg i.v.)
Number of subjects: 6
Study 10870037 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (GLU; 0.017 mg/kg i.m.) + AVP (0.17 U/kg i.m.)
Number of subjects: 6
Study 10870037 — intervention group
Group type: COMPARATOR
Intervention: hCRH + AVP
Number of subjects: 6
Study 9195148 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (0.56 mg bid)
Number of subjects: 243
Study 9195148 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (0.2 mg bid)
Number of subjects: 243
Study 9195148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 9114912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 16
Study 9114912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 16
Study 9114912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 800 mg
Number of subjects: 16
Study 9114912 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg
Number of subjects: 16
Study 9114912 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 16
Study 9114912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3542917 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium therapy
Number of subjects: 45
Study 31755993 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical omiganan 2.5%
Number of subjects: 36
Study 31755993 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study 30394834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightly controlled renoprotective protocol including regular clinical evaluations, blood pressure management, and glucocorticoid dose reduction if indicated.
Number of subjects: 13
Study 30394834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tightly controlled renoprotective protocol
Number of subjects: 13
Study 27531132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 27531132 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 27531132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24164309 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel (0.5% w/w), applied four times a day for 5 days
Number of subjects: 90
Study 24164309 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrrh gel (0.5% w/w), applied four times a day for 5 days
Number of subjects: 90
Study 24164309 — intervention group
Group type: COMPARATOR
Intervention: Plain mucoadhesive gel (placebo), applied four times a day for 5 days
Number of subjects: 90
Study 22172430 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 infusions of a multicomponent disodium EDTA chelation solution
Number of subjects: 1708
Study 22172430 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, high-dose multivitamin and mineral supplement
Number of subjects: 1708
Study 22172430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study 22172430 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life outcomes (900-patient substudy)
Number of subjects: 1708
Study 20797891 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (preop-RT) with chemotherapy (CT)
Number of subjects: 0
Study 20797891 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy (preop-RT) without chemotherapy (Control)
Number of subjects: 0
Study 18402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular doses of CBM588
Number of subjects: 19
Study 18402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Double doses of CBM588
Number of subjects: 19
Study 18402597 — intervention group
Group type: COMPARATOR
Intervention: Without probiotics (Control Group A)
Number of subjects: 19
Study 18402597 — intervention group
Group type: COMPARATOR
Intervention: Regular doses of CBM588 (Group B)
Number of subjects: 19
Study 18402597 — intervention group
Group type: EXPERIMENTAL
Intervention: Double doses of CBM588 (Group C)
Number of subjects: 19
Study 15733717 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral tube feeding
Number of subjects: 1180
Study 15733717 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG) feeding
Number of subjects: 1180
Study 15733717 — intervention group
Group type: COMPARATOR
Intervention: No tube feeding for more than 7 days
Number of subjects: 1180
Study 12928996 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific stabilizing exercise of the M. multifidus and M. transversus abdominis
Number of subjects: 99
Study 12928996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 99
Study 10489788 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation programs during pregnancy
Number of subjects: 9000
Study 10489788 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity smoking cessation interventions
Number of subjects: 9000
Study 10489788 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated smoking cessation interventions
Number of subjects: 9000
Study 10489788 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality smoking cessation interventions
Number of subjects: 9000
Study 10489788 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking relapse prevention programs
Number of subjects: 9000
Study 10489788 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation programs
Number of subjects: 9000
Study 10489788 — intervention group
Group type: COMPARATOR
Intervention: Single large cluster-randomized trial
Number of subjects: 9000
Study 8646946 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms bolus injection)
Number of subjects: 8
Study 8646946 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (10 micrograms bolus injection)
Number of subjects: 8
Study 8646946 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (250 micrograms/hour infusion)
Number of subjects: 8
Study 8646946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1655867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial Adriamycin (60 mg/m2) with lipiodol (10 ml)
Number of subjects: 16
Study 1655867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial Adriamycin (60 mg/m2) without lipiodol
Number of subjects: 16
Study 1655867 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Adriamycin (60 mg/m2)
Number of subjects: 16
Study 6344591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid therapy
Number of subjects: 6
Study 31989151 — intervention group
Group type: EXPERIMENTAL
Intervention: roluperidone 32 mg
Number of subjects: 244
Study 31989151 — intervention group
Group type: EXPERIMENTAL
Intervention: roluperidone 64 mg
Number of subjects: 244
Study 31989151 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 244
Study 30097364 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional formula enriched with Omega-3 fatty acids (O3FA)
Number of subjects: 40
Study 30097364 — intervention group
Group type: COMPARATOR
Intervention: Preoperative balanced energy high-protein formula (Control Group)
Number of subjects: 40
Study 28074235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and CNS radiotherapy
Number of subjects: 33
Study 28074235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 33
Study 28074235 — intervention group
Group type: COMPARATOR
Intervention: Control group (newly diagnosed children)
Number of subjects: 33
Study 28074235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treated groups (chemotherapy alone and chemotherapy with CNS radiotherapy)
Number of subjects: 33
Study 26022945 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 3 months
Number of subjects: 224
Study 26022945 — intervention group
Group type: COMPARATOR
Intervention: No CPAP treatment for 3 months
Number of subjects: 224
Study 23143842 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 960 mg twice daily
Number of subjects: 181
Study 22134457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Differentiation Program in Individualized Sessions (CDi)
Number of subjects: 26
Study 22134457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Differentiation Program in Group Sessions (CDg)
Number of subjects: 26
Study 19822510 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Number of subjects: 125
Study 19822510 — intervention group
Group type: COMPARATOR
Intervention: Racemic leucovorin
Number of subjects: 125
Study 15918064 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoseal (10 ml)
Number of subjects: 50
Study 15249566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 522
Study 15249566 — intervention group
Group type: COMPARATOR
Intervention: Comparison
Number of subjects: 522
Study 10908002 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix model, a manualized program of intensive outpatient treatment
Number of subjects: 150
Study 10908002 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 150
Study 9364851 — intervention group
Group type: EXPERIMENTAL
Intervention: MR venography with tourniquet after leg-warming
Number of subjects: 8
Study 9364851 — intervention group
Group type: COMPARATOR
Intervention: MR venography
Number of subjects: 8
Study 9364851 — intervention group
Group type: COMPARATOR
Intervention: MR venography with tourniquet around the knee
Number of subjects: 8
Study 9364851 — intervention group
Group type: COMPARATOR
Intervention: MR venography after leg-warming
Number of subjects: 8
Study 8455074 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg.kg-1 i.v. over 20 min)
Number of subjects: 8
Study 8455074 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 3778565 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐mg urapidil slow release‐capsule
Number of subjects: 12
Study 3778565 — intervention group
Group type: COMPARATOR
Intervention: 30‐mg urapidil drinking ampoule (Ebrantil)
Number of subjects: 12
Study 29798745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/Piperaquine
Number of subjects: 0
Study 29798745 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study 28062468 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived 10-year cardiovascular risk estimation using a 3-item scale (high-risk, moderate-risk, low-risk)
Number of subjects: 514
Study 28062468 — intervention group
Group type: EXPERIMENTAL
Intervention: Underestimation of 10-year cardiovascular risk
Number of subjects: 514
Study 25468398 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone motivational interviewing intervention (Beating Fatigue)
Number of subjects: 44
Study 23359371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 48
Study 23359371 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 48
Study 20800381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate (MMF)
Number of subjects: 176
Study 20800381 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 176
Study 18574645 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients
Number of subjects: 70
Study 18574645 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients at 60 degrees head rotation
Number of subjects: 70
Study 18574645 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients at 0 degrees head rotation
Number of subjects: 70
Study 18574645 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients at 30 degrees head rotation
Number of subjects: 70
Study 18574645 — intervention group
Group type: COMPARATOR
Intervention: Simulated IJV puncture in nonobese patients
Number of subjects: 70
Study 16583726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 361
Study 16583726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 361
Study 16583726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 14633753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 33
Study 14633753 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 33
Study 12422059 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-30 mg/day)
Number of subjects: 44
Study 12422059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (targeted to 190-570 nmol/l)
Number of subjects: 44
Study 9589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 10
Study 9589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.5 mg
Number of subjects: 10
Study 9589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg/naloxone 0.5 mg
Number of subjects: 10
Study 9589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 15 mg
Number of subjects: 10
Study 9589267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8024075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (1,250 mg divided between two doses of 750 and 500 mg six hours apart) plus doxycycline (200 mg once a day for seven days)
Number of subjects: 109
Study 8024075 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (300 mg total for 2.5 days; 100 mg followed by 50 mg every 12 hr for 2.5 days) plus doxycycline (200 mg once a day for seven days)
Number of subjects: 109
Study 2645244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioversol
Number of subjects: 120
Study 2645244 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 120
Study 2645244 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 120
Study 30901951 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training program (6 weeks, 2 times per week for 75 min)
Number of subjects: 122
Study 30901951 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training program
Number of subjects: 122
Study 30901951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study 28167214 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis assisted by Doppler monitoring of blood flow (n=72)
Number of subjects: 148
Study 28167214 — intervention group
Group type: COMPARATOR
Intervention: Standard, visually guided endoscopic hemostasis (control, n=76)
Number of subjects: 148
Study 25887312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial and multidisciplinary intervention
Number of subjects: 328
Study 25887312 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 328
Study 25887312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial and multidisciplinary intervention in subjects with nutritional risk
Number of subjects: 328
Study 23946124 — intervention group
Group type: EXPERIMENTAL
Intervention: Carers' expressed emotion and level of psychological control
Number of subjects: 152
Study 23946124 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting interpersonal maintaining factors such as carer distress
Number of subjects: 152
Study 21415616 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care management services pilot program
Number of subjects: 0
Study 19622463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m², Cyclophosphamide 1000 mg/m², Vincristine 1.4 mg/m² (max 2 mg), Prednisone 50 mg every other day for 30 days, G-CSF on days 7-10 after each cycle
Number of subjects: 10
Study 17890860 — intervention group
Group type: EXPERIMENTAL
Intervention: cuprammonium membrane
Number of subjects: 14
Study 15548216 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream (EMLA) applied for forearm skin anaesthesia
Number of subjects: 20
Study 15548216 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream (EMLA)
Number of subjects: 20
Study 15548216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11535502 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children (age not specified)
Number of subjects: 698
Study 11535502 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children (age not specified)
Number of subjects: 698
Study 10947374 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 0
Study 10947374 — intervention group
Group type: COMPARATOR
Intervention: Discussion Group use of CHESS
Number of subjects: 0
Study 8068212 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide and hydrocortisone
Number of subjects: 322
Study 8068212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 8068212 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane
Number of subjects: 322
Study 8068212 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus aminoglutethimide/hydrocortisone
Number of subjects: 322
Study 8068212 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 322
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Wine (RW)
Number of subjects: 54
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: White Wine (WW)
Number of subjects: 54
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vodka (VDK)
Number of subjects: 54
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Meal (MeDM)
Number of subjects: 54
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat Meal (HFM)
Number of subjects: 54
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM + Red Wine (RW)
Number of subjects: 54
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM + White Wine (WW)
Number of subjects: 54
Study 30050655 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM + Vodka (VDK)
Number of subjects: 54
Study 26936358 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/d ibuprofen (IBU)
Number of subjects: 0
Study 26936358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study 24734285 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-standardized subcutaneous immunotherapy (SCIT)
Number of subjects: 40
Study 24734285 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy tablets (SLIT tablet)
Number of subjects: 40
Study 24734285 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither SCIT nor SLIT tablet)
Number of subjects: 40
Study 22484377 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% strontium acetate in silica base
Number of subjects: 28
Study 22484377 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine, calcium carbonate, 1450 ppm sodium monofluorophosphate (Colgate Sensitive Pro‐Relief(®))
Number of subjects: 28
Study 22484377 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm sodium fluoride (control paste)
Number of subjects: 28
Study 22484377 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 28
Study 20110249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (30‐180 mg/day) plus low‐dose active vitamin D
Number of subjects: 360
Study 20110249 — intervention group
Group type: COMPARATOR
Intervention: Flexible dosing of active vitamin D alone
Number of subjects: 360
Study 18427279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/d
Number of subjects: 65
Study 18427279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 16005552 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined influenza and pneumococcal vaccination
Number of subjects: 690
Study 16005552 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza alone
Number of subjects: 690
Study 16005552 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccination (control)
Number of subjects: 690
Study 12957502 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (SP) at 10(‐9) M
Number of subjects: 22
Study 12957502 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (SP) at 10(‐6) M
Number of subjects: 22
Study 9894960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic group (target temperature of 33.5 degrees C)
Number of subjects: 114
Study 9894960 — intervention group
Group type: COMPARATOR
Intervention: Normothermic group (target esophageal temperature at clip application of 36.5 degrees C)
Number of subjects: 114
Study 9894960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114